Royalty Pharma (RPRX) Divestments (2020 - 2026)
Royalty Pharma (RPRX) posted Divestments of $42.3 million for Q1 2026, up 747.14% sequentially from $5.0 million in Q4 2025, and up 16.67% YoY from $36.3 million in Q1 2025.
Royalty Pharma (RPRX) Divestments (2020 - 2026) Analysis & Trends
Royalty Pharma has reported Divestments for 7 years, with the latest figure at $42.3 million in Q1 2026.
- Quarterly Divestments rose 16.67% year-over-year to $42.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.6 million (up 103.3% YoY) and the FY2025 annual result came in at $105.1 million, up 344.77% from the prior year.
- Divestments climbed to $42.3 million in Q1 2026 per RPRX's latest filing, from $5.0 million in the prior quarter.
- Over five years, Divestments peaked at $62.4 million in Q2 2025 and troughed at $905000.0 in Q3 2025.
- A 5-year average of $15.3 million and a median of $5.0 million in 2025 frame the typical range for Divestments.
- The widest YoY moves for Divestments: up 1500.0% in 2025, down 91.77% in 2025.
- Over 5 years, Divestments stood at $5.8 million in 2022, then decreased by 19.71% to $4.7 million in 2023, then plunged by 30.34% to $3.2 million in 2024, then jumped by 53.95% to $5.0 million in 2025, then soared by 747.14% to $42.3 million in 2026.
- According to Business Quant data, Divestments over the past three periods registered $42.3 million, $5.0 million, and $905000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 9.82 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -13.21 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.21 Mn |
| Mar 31, 2026 | 42.31 Mn |
| Dec 31, 2025 | 4.99 Mn |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 62.40 Mn |
| Mar 31, 2025 | 36.26 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 11.00 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Mar 31, 2024 | 4.97 Mn |
| Dec 31, 2023 | 4.66 Mn |
| Sep 30, 2023 | 4.80 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 34.77 Mn |
| Sep 30, 2022 | 5.80 Mn |
| Jun 30, 2022 | 6.80 Mn |
| Sep 30, 2021 | 6.20 Mn |
| Jun 30, 2021 | 4.70 Mn |
| Sep 30, 2020 | 4.20 Mn |
| Jun 30, 2020 | 5.30 Mn |